Product Description
Mechanisms of Action: ADORA2 Agonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Acorda
Company Location: ARDSLEY NY 10502
Company CEO: Ron Cohen
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Parkinson's Disease
Phase 1: Healthy Volunteers|Cocaine-Related Disorders|Hepatic Insufficiency|Liver Failure
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2016-003961-25 | P3 |
Terminated |
Parkinson's Disease |
2020-06-30 |
|
| TOZ-PD | P3 |
Completed |
Parkinson's Disease |
2019-04-29 |
|
| TOZ-CL06 | P3 |
Terminated |
Parkinson's Disease |
2018-01-16 |
79% |
| TOZ-PD | P3 |
Terminated |
Parkinson's Disease |
2018-01-12 |